Subtype
Lung Non-Small Cell Carcinoma with Genetic Abnormalities
CI-CAN-00005823Explore in graph →
10 active trials4 approved drugs
- NCIt
- C227212
Loading cancer entity…
Subtype
CI-CAN-00005823Explore in graph →
Clinical trials
31 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (5)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05482087 | A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC | unknown | Phase 2 | 190 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 1, 2022 | clinicaltrials |
| NCT04056572 | Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib | unknown | Phase 2 | 135 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 30, 2019 |
| clinicaltrials |
| NCT03972189 | Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 111 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 15, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Aug 1, 2022source: clinicaltrials